As the mammalian target of rapamycin (mTOR) inhibitor-based immunosuppression seems to show improved recurrence-free survival and better overall survival rates in HCC recipients of LT, their use in malignant indications is of great interest (32, 33). This evidence concerns the gene MTOR and hepatocellular carcinoma.